| Code | CSB-RA004954MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to IMM-40H, designed for research targeting CD70, a type II transmembrane glycoprotein member of the tumor necrosis factor (TNF) superfamily. CD70 serves as the ligand for CD27, playing a critical role in T cell and B cell activation, differentiation, and survival. Under normal physiological conditions, CD70 expression is tightly regulated and transiently induced on activated lymphocytes and mature dendritic cells. However, aberrant CD70 expression has been documented in various hematological malignancies including non-Hodgkin lymphoma, multiple myeloma, and acute lymphoblastic leukemia, as well as in solid tumors such as renal cell carcinoma and glioblastoma, where it contributes to immune evasion and tumor progression.
IMM-40H is a humanized, defucosylated anti-CD70 monoclonal antibody designed to inhibit the binding of CD70 to CD27, thereby blocking the pro-tumor survival signal. It also directly eliminates tumor cells expressing CD70 through enhancing antibody-dependent cell cytotoxicity (ADCC). Currently, IMM-40H is in the first/second phase of clinical trials, where its safety, tolerability, and preliminary efficacy in treating CD70-positive hematological malignancies and solid tumors (such as renal cell carcinoma, acute myeloid leukemia, etc.) are being evaluated. This biosimilar antibody provides researchers with a reliable reagent for studying CD70 biology, exploring its therapeutic potential in cancer immunotherapy, and evaluating CD70-CD27 interactions in disease models.
There are currently no reviews for this product.